To include your compound in the COVID-19 Resource Center, submit it here.

With $50M from Versant, Lycia takes targeted degradation outside the cell

Lycia, co-founded by Carolyn Bertozzi, cracks open the world of targeted degradation of extracellular proteins

Fourteen months after leading biochemist Carolyn Bertozzi published a preprint on a new class of compounds that degrade extracellular proteins inaccessible to PROTACs, Versant-built Lycia has emerged with $50 million to turn that technology into therapies.

“We saw this as an opportunity for completely new ways of doing protein degradation focused on extracellular proteins, which make up about 40% of proteins overall,” said Versant Ventures’ Clare Ozawa.

The company’s LYTAC (lysosomal targeting chimera) technology

Read the full 729 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE